Medexus Pharmaceuticals (TSE:MDP) Downgraded by Bloom Burton

Bloom Burton lowered shares of Medexus Pharmaceuticals (TSE:MDPGet Rating) from a hold rating to a sell rating in a report published on Tuesday, reports.

Medexus Pharmaceuticals Stock Down 4.3 %

MDP stock opened at C$1.10 on Tuesday. The stock’s 50 day simple moving average is C$2.32 and its 200 day simple moving average is C$2.52. Medexus Pharmaceuticals has a fifty-two week low of C$1.05 and a fifty-two week high of C$3.86. The company has a debt-to-equity ratio of 327.43, a quick ratio of 0.44 and a current ratio of 0.97. The company has a market cap of C$21.95 million and a P/E ratio of 6.88.

Medexus Pharmaceuticals (TSE:MDPGet Rating) last posted its quarterly earnings results on Wednesday, June 22nd. The company reported C($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.40) by C$0.11. The firm had revenue of C$25.67 million for the quarter, compared to analyst estimates of C$21.69 million. On average, research analysts expect that Medexus Pharmaceuticals will post 0.05 earnings per share for the current fiscal year.

About Medexus Pharmaceuticals

(Get Rating)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.

Featured Stories

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.